Found: 27
Select item for more details and to access through your institution.
Bridging Health Disparities: a Genomics and Transcriptomics Analysis by Race in Prostate Cancer.
- Published in:
- Journal of Racial & Ethnic Health Disparities, 2024, v. 11, n. 1, p. 492, doi. 10.1007/s40615-023-01534-4
- By:
- Publication type:
- Article
Androgen receptor splice variant 7 (AR‐V7) and AR full‐length (AR‐FL) as predictive biomarkers of therapeutic resistance: partners in crime?
- Published in:
- BJU International, 2019, v. 124, n. 4, p. 549, doi. 10.1111/bju.14869
- By:
- Publication type:
- Article
Coordinating Etk/Bmx activation and VEGF upregualtion to promote cell survival and proliferation.
- Published in:
- Oncogene, 2002, v. 21, n. 57, p. 8817, doi. 10.1038/sj.onc.1206032
- By:
- Publication type:
- Article
Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3.
- Published in:
- Journal of Cancer, 2024, v. 15, n. 3, p. 615, doi. 10.7150/jca.90836
- By:
- Publication type:
- Article
Targeting neddylation sensitizes colorectal cancer to topoisomerase I inhibitors by inactivating the DCAF13-CRL4 ubiquitin ligase complex.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39374-9
- By:
- Publication type:
- Article
Role of cereblon in angiogenesis and in mediating the antiangiogenic activity of immunomodulatory drugs.
- Published in:
- FASEB Journal, 2020, v. 34, n. 9, p. 11395, doi. 10.1096/fj.201903060RR
- By:
- Publication type:
- Article
Antiangiogenic Activity and in Silico Cereblon Binding Analysis of Novel Thalidomide Analogs.
- Published in:
- Molecules, 2020, v. 25, n. 23, p. 5683, doi. 10.3390/molecules25235683
- By:
- Publication type:
- Article
Genomic Characterization of Preclinical Prostate Cancer Cell Line Models.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 11, p. 6111, doi. 10.3390/ijms25116111
- By:
- Publication type:
- Article
COVID‐19 Clinical Diagnostics and Testing Technology.
- Published in:
- Pharmacotherapy, 2020, v. 40, n. 8, p. 857, doi. 10.1002/phar.2439
- By:
- Publication type:
- Article
Pharm.D. Pathways to Biomedical Research: The National Institutes of Health Special Conference on Pharmacy Research.
- Published in:
- 2008
- By:
- Publication type:
- Proceeding
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single‐Dose Administration Under Fasting Conditions in Prostate Cancer.
- Published in:
- Oncologist, 2021, v. 26, n. 9, p. 729, doi. 10.1002/onco.13919
- By:
- Publication type:
- Article
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
- Published in:
- Oncologist, 2021, v. 26, n. 1, p. e115, doi. 10.1634/theoncologist.2020-0697
- By:
- Publication type:
- Article
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.
- Published in:
- Scientific Reports, 2019, v. 9, n. 1, p. N.PAG, doi. 10.1038/s41598-019-51446-9
- By:
- Publication type:
- Article
Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.
- Published in:
- Scientific Reports, 2016, p. 30038, doi. 10.1038/srep30038
- By:
- Publication type:
- Article
Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma.
- Published in:
- Biomolecules (2218-273X), 2024, v. 14, n. 6, p. 725, doi. 10.3390/biom14060725
- By:
- Publication type:
- Article
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2013, v. 111, n. 8, p. 1269, doi. 10.1111/j.1464-410X.2012.11667.x
- By:
- Publication type:
- Article
TMPRSS2: Potential Biomarker for COVID‐19 Outcomes.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 7, p. 801, doi. 10.1002/jcph.1641
- By:
- Publication type:
- Article
Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-90143-4
- By:
- Publication type:
- Article
Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-84960-w
- By:
- Publication type:
- Article
Crosstalk of hypoxia-mediated signaling pathways in upregulating plasminogen activator inhibitor-1 expression in keloid fibroblasts.
- Published in:
- Journal of Cellular Physiology, 2004, v. 199, n. 1, p. 89, doi. 10.1002/jcp.10452
- By:
- Publication type:
- Article
Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.
- Published in:
- Cancers, 2021, v. 13, n. 9, p. 2154, doi. 10.3390/cancers13092154
- By:
- Publication type:
- Article
Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 12, p. 1484, doi. 10.1002/jcph.765
- By:
- Publication type:
- Article
Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures.
- Published in:
- Journal of Hematology & Oncology, 2012, v. 5, n. 1, p. 35, doi. 10.1186/1756-8722-5-35
- By:
- Publication type:
- Article
Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.
- Published in:
- PLoS ONE, 2015, v. 10, n. 5, p. 1, doi. 10.1371/journal.pone.0126672
- By:
- Publication type:
- Article
Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models.
- Published in:
- Marine Drugs, 2018, v. 16, n. 7, p. 241, doi. 10.3390/md16070241
- By:
- Publication type:
- Article
Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
- Published in:
- Molecular Cancer, 2014, v. 13, n. 1, p. 1, doi. 10.1186/1476-4598-13-91
- By:
- Publication type:
- Article